NCT06493955Not yet recruiting
Evaluation of the Effectiveness of Extending the "Passerelle" System for Prescribing Adapted Physical Activity to Patients With Type 2 Diabetes in Nouvelle-AQUItaine (France)
Source: ClinicalTrials.gov · Last updated 7 Aug 2026
Brief summary (registry, in English)
Type 2 diabetes is on the increase worldwide. Two major risk factors have been identified: overweight and physical inactivity. National and international recommendations encourage general practitioner to guide patients in changing their lifestyle. As regards physical activity in France, general practitioner have been able to prescribe adapted physical activity (APA) for their patients since 2016. In type 2 diabetes, it is known that physical activity interventions are cost-effective. However, these interventions are often too expensive and far removed from real life. It is also known that the benefits of intervention increase up to 18 months, then diminish to zero at 36 months. In Nouvelle-Aquitaine, France, the "PEPS Sport-santé network", offers physical activity coaching for patients who are not sufficiently active: the "Passerelle" program. Patients can benefit from a weekly physical activity session for 6 months. The investigators would therefore like to assess whether extending the existing "Passerelle program" by 6 months, with one session every 15 days, is effective in maintaining the volume of physical activity 12 months after the end of the intervention.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 308 (estimated)
- First submitted
- 2 Jul 2024
- Start date
- Sept 2026
- Primary completion date
- Sept 2029
- Lead sponsor
- University Hospital, Bordeaux
- Diseases
- Type 2 diabetes
- NCT number
- NCT06493955
What you commit to
- Study type: Interventional
- Planned participants: 308
- From Sept 2026 to the primary completion date, Sept 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Cardiovascular: unstable angina, stress angina, malignant hypertension, recent myocardial infarction, unstabilized heart disease
Lab values
- Endocrine: diabetes with HbA1c \> 9%, plantar perforator disease
Other
- Patient with any other unstabilized pathology:
- Pulmonary: uncontrolled asthma, COPD exacerbation
- Pregnant patient
- Diabetic patient with contraindication to APA prescription
- Patient under court protection
Who the study is looking for
- Patients with type 2 diabetes with initial diagnosis of fasting blood glucose \> 1.26 g/l on 2 occasions
- Patient aged 18 or over
- Patient with a Marshall score ≤ 3
- Patient residing in the Nouvelle-Aquitaine region
- Patient eligible for the "Passerelle" program
- Patient willing to participate
- Patient agreeing to take part in the study and having signed an informed consent form
- Person affiliated or benefiting from a social security scheme.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Cabinet Médical Bergerac Coordinator of this site? Confirm its status | Bergerac | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.